PubMed HealthSearch

Biomedical subjects

Chen Qian

Publications and source records attributed to Chen Qian.

2 recordsLinked to original sources

Advancing proteomic discovery through optimized multi-stage scoring and deep learning-enhanced open search.

MOTIVATION: Protein search engines are essential for interpreting mass spectrometry data into biological insight. Current tools often face limitations in sensitivity when analyzing complex modern datasets, and lack a unified framework that effectively integrates deep learning features for both restricted and open searches, especially for scenarios aimed at discovering unknown modifications. RESULTS: We present pFind+, a high-performance search engine for data-dependent acquisition (DDA) proteomics, extending pFind. It introduces an enhanced raw scoring that delivers substantially improved pre-filtering ability, while recovering most of the computational overhead through a tailored acceleration strategy. Coupled with an enhanced rescoring framework that effectively integrates deep learning features, pFind+ uniquely supports high-sensitivity, DL-enhanced open search, enabling comprehensive PTM discovery while incorporating hardware-aware inference optimizations for practical deployment. Evaluations across diverse datasets demonstrate its superior sensitivity, with gains of 12.7%-29.3% (average 17.9%) in restricted search and 8.0%-38.4% (average 25.8%) in open search over the best existing tools.

Deep Learning

A comprehensive meta-analysis of tissue resident memory T cells and their roles in shaping immune microenvironment and patient prognosis in non-small cell lung cancer.

Tissue-resident memory T cells (TRM) are a specialized subset of long-lived memory T cells that reside in peripheral tissues. However, the impact of TRM-related immunosurveillance on the tumor-immune microenvironment (TIME) and tumor progression across various non-small-cell lung cancer (NSCLC) patient populations is yet to be elucidated. Our comprehensive analysis of multiple independent single-cell and bulk RNA-seq datasets of patient NSCLC samples generated reliable, unique TRM signatures, through which we inferred the abundance of TRM in NSCLC. We discovered that TRM abundance is consistently positively correlated with CD4+ T helper 1 cells, M1 macrophages, and resting dendritic cells in the TIME. In addition, TRM signatures are strongly associated with immune checkpoint and stimulatory genes and the prognosis of NSCLC patients. A TRM-based machine learning model to predict patient survival was validated and an 18-gene risk score was further developed to effectively stratify patients into low-risk and high-risk categories, wherein patients with high-risk scores had significantly lower overall survival than patients with low-risk. The prognostic value of the risk score was independently validated by the Cancer Genome Atlas Program (TCGA) dataset and multiple independent NSCLC patient datasets. Notably, low-risk NSCLC patients with higher TRM infiltration exhibited enhanced T-cell immunity, nature killer cell activation, and other TIME immune responses related pathways, indicating a more active immune profile benefitting from immunotherapy. However, the TRM signature revealed low TRM abundance and a lack of prognostic association among lung squamous cell carcinoma patients in contrast to adenocarcinoma, indicating that the two NSCLC subtypes are driven by distinct TIMEs. Altogether, this study provides valuable insights into the complex interactions between TRM and TIME and their impact on NSCLC patient prognosis. The development of a simplified 18-gene risk score provides a practical prognostic marker for risk stratification.

Humans